Get to know our clinical trials
Datopotamab Deruxtecan (Dato- DXd) trial in patients with inoperable locally recurrent inoperable or metastatic PD-L1-positive triple-negative breast cancer
IN THIS TRIAL, WE WILL COMPARE THE INVESTIGATIONAL TREATMENT WITH THE REFERENCE CHEMOTHERAPY (EITHER PACLITAXEL, NAB-PACLITAXEL OR GEMCITABINE CARBOPLATIN) IN COMBINATION WITH PEMBROLIZUMAB. THIS TRIAL WILL ALSO HELP US TO BETTER UNDERSTAND THE DISEASE BEING STUDIED AND THE HEALTH PROBLEMS ASSOCIATED WITH IT.
Technical Summary
- PHASE 3, OPEN-LABEL, RANDOMIZED TRIAL OF DATOPOTAMAB DERUXTECAN (DATO- DXD) WITH OR WITHOUT DURVALUMAB COMPARED TO THE INVESTIGATOR'S CHEMOTHERAPY OF CHOICE (PACLITAXEL, NAB-PACLITAXEL OR GEMCITABINE AND CARBOPLATIN) IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH INOPERABLE OR METASTATIC, PD-L1-POSITIVE, LOCALLY RECURRENT TRIPLE-NEGATIVE BREAST CANCER (TROPION-BREAST05).
- Code EudraCT: 2023-503675-24
- Protocol number: D7630C00001
- Promoter: Astra Zeneca AB
- Molecule/Drug: Datopotamab Deruxtecan
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.